Dynamics of Some Routine Immunological Parameters During Anti - TNF Therapy in Patients with Crohn’s Disease
Background: Fecal and immunological biomarkers can be used to diagnose and manage patients with Crohn’s disease (CD). Anti -tumor necrosis factor (TNF) should be evaluated in addition to biomarkers to determine the response to therapy.Objectives: The current study aimed at following up fe...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Shiraz University of Medical Sciences
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1b051dfe7da24b779665674fcd79b43c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Background: Fecal and immunological biomarkers can be used to diagnose and manage patients with Crohn’s disease (CD). Anti -tumor necrosis factor (TNF)
should be evaluated in addition to biomarkers to determine the response to therapy.Objectives: The current study aimed at following up fecal calprotectin (FC), perinuclear anti - neutrophil
cytoplasmic antibodies(pANCA), anti - Saccharomyces cerevisiae antibodies (ASCA), and anti - nuclear antibodies (ANA) in patients with CD on anti-TNFtherapy.Methods: A total of 57 patients
with CD and the mean age of 40±15 years (ranged: 20 - 75) were monitored after initiation of anti- TNFa treatment. Stool samples were tested for FC (Alegria automated the enzyme - linked
immunosorbent assay (ELISA) system),and serum samples for ANCA, ANA (indirect immunofluorescence - IIF), and ASCA (ELISA) in the beginning and after six months onimmunosuppressive
therapy plus anti - TNFa agents.Results: Itwasobserved that all patients withCDhadsignificantly decreased FC levels after anti -TNFatherapy (963.97mg/kginitiallyvs. 268.42 mg/kg
after treatment; P = 0.043). Moreover, in 75% of patients, FC levels dropped below the cutoff value of 50 mg/kg.Positive for ASCAIgA/IgG were 17/24 tested patients,
butnodifferences were observed regarding the application of anti - TNFa therapy.However, the titers of pANCA decreased in four patients after anti - TNFa treatment.
Conclusions: Initial and follow - up measurements of some immunological markers such as FC and pANCA could be of benefit forpatients with CD in anti - TNF therapy,
whereas others such as ANA and ASCA were not useful to monitor the therapy. |
|---|